Johnson & Johnson

The filing data shows a large business whose reported net income grew faster than its revenue, and a few items deserve a closer read. Revenue grew 6.0% to $94.19 billion, while net income rose about 90% to $26.8 billion from $14.07 billion. Two forensic figures are available for this synthesis. The operating cash flow to net income ratio is 0.92, which equals operating cash flow of $24.53 billion divided by net income of $26.8 billion. Put plainly, about 92 cents of operating cash came in for each dollar of reported 2025 profit, so net income ran somewhat ahead of cash generation this year. A ratio below 1 is common and is not by itself a conclusion about earnings quality. For comparison, the same ratio for 2024 works out to about 1.72, using operating cash flow of $24.27 billion and net income of $14.07 billion. The data provided includes no label for this ratio, so this synthesis does not assign it a zone. The Beneish M-Score, Altman Z-Score, Piotroski F-Score and Fog Index are not on file for this synthesis, so no values are given for them. The MD&A describes the planned separation of the Orthopaedics business, announced in October 2025 with a targeted completion within 18 to 24 months. Readers may want to look at how that separation is presented in future segment reporting. The balance sheet shows liabilities of $117.67 billion against equity of $81.54 billion. Readers may want to look at the debt discussion in Item 8 to see how the increase in long-term debt is structured.

Catalyst.Revenue for fiscal 2025 reached $94.19 billion, up 6.0% from $88.82 billion in 2024. The MD&A points to the Innovative Medicine segment, led by DARZALEX and DARZALEX FASPRO, which together accounted for approximately 15.0% of total revenues in fiscal 2025. Newer multiple myeloma and lung cancer products named in the filing, including CARVYKTI, TECVAYLI, TALVEY and RYBREVANT, are described as active growth lines. The MedTech segment, which includes Abiomed and Shockwave cardiovascular products and ACUVUE contact lenses, is the second reporting segment. Reported net income rose to $26.8 billion from $14.07 billion in 2024.

Hidden risk.Revenue exposure to patent expiry and pricing is the tension a casual reader could miss. STELARA accounted for approximately 6.5% of fiscal 2025 revenues, and the filing says the company expects continued biosimilar launches to keep reducing its sales. DARZALEX's two US patent families expire in 2029, and Genmab royalties on DARZALEX sales were approximately $2.4 billion in 2025. The filing also says the Inflation Reduction Act has subjected certain products to government-established pricing beginning in 2026. Meanwhile, long-term debt increased to $39.44 billion from $30.65 billion.